

Date: 26th May, 2021

To,
Mr. Sareesh Koroth, Chief Manager
Surveillance
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir,

**Sub.: Clarification / Confirmation on news item appearing in
“Media/Publication”**

Letter Ref. No.: NSE/CM/Surveillance/10765 dated 26th May, 2021

With reference to the captioned matter and your above referred letter, we would like to confirm that the Company has received license to manufacture Liposomal Amphotericin B Injection 50 mg/Vial (Lyophilized) from Drugs Controller General of India and Food & Drug Control Authority, Gujarat.

The Company is trying to work on its supply chain and manufacturing operations to bring the product to the Indian patients at the earliest.

For any pharmaceutical company, it is in regular course of business to get approvals from regulators for manufacturing pharmaceutical products. The referred license does not have material impact on the Company and hence it was not informed.

At this moment we have no other comments to offer.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123